Clostridioides difficile Associated Enteropathy (Clostridium difficile Associated Enteropathy) - Pipeline Review, H2 2020
Clostridioides difficile Associated Enteropathy (Clostridium difficile Associated Enteropathy) - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridioides difficile Infections - Pipeline Review, H2 2020, provides an overview of the Clostridioides difficile Infections (Infectious Disease) pipeline landscape.
Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridioides difficile Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Clostridioides difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Clostridioides difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridioides difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 10, 12, 42, 20 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 7 molecules, respectively.
Clostridioides difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridioides difficile Infections - Pipeline Review, H2 2020, provides an overview of the Clostridioides difficile Infections (Infectious Disease) pipeline landscape.
Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridioides difficile Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Clostridioides difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Clostridioides difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridioides difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 10, 12, 42, 20 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 7 molecules, respectively.
Clostridioides difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridioides difficile Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Clostridioides difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Clostridioides difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Clostridioides difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Clostridioides difficile Infections (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Clostridioides difficile Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Clostridioides difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Overview
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Development
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Drug Profiles
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones
Appendix
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Overview
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Development
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Drug Profiles
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Absynth Biologics Ltd, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Acurx Pharmaceuticals LLC, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Appili Therapeutics Inc, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Artugen Therapeutics Ltd, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Aviex Technologies LLC, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AzurRx BioPharma Inc, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Biomica, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Botanix Pharmaceuticals Ltd, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Boulos and Cooper Pharmaceuticals Pty Ltd, H2 2020
Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Absynth Biologics Ltd, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Acurx Pharmaceuticals LLC, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Appili Therapeutics Inc, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Artugen Therapeutics Ltd, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Aviex Technologies LLC, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AzurRx BioPharma Inc, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Biomica, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Botanix Pharmaceuticals Ltd, H2 2020
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Boulos and Cooper Pharmaceuticals Pty Ltd, H2 2020
LIST OF FIGURES
Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
